Q-omics provides the consensus-scored RPL26P28 profile across patient tissues and cancer cell-line models. RPL26P28 expression is associated with patient survival in 10 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, RPL26P28 is differentially expressed in 6, with the highest sampling consensus in HNSC. Additionally, RPL26P28 RNA expression shows 6,865 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight ACC, HNSC, and LSCC as cancer lineages where RPL26P28 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RPL26P28 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RPL26P28 survival associations across molecular data types. RPL26P28 RNA expression shows survival associations in the most cancer types (10). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RPL26P28 RNA expression–survival associations across cancer types. High RPL26P28 expression shows unfavorable associations in ACC, UVM, LUAD and STAD, but favorable associations in CESC and BLCA. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for RPL26P28 RNA expression.
This table summarizes RPL26P28 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 6. The strongest signals are observed in HNSC for RNA.
This table ranks reproducible tumor–normal expression differences for RPL26P28. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RPL26P28 shows lower tumor expression in BLCA and LIHC and higher tumor expression in HNSC, LUSC, COAD and KIRC. The HNSC box plot shows higher RPL26P28 RNA expression in tumor versus normal tissue (log2 FC = +0.054, t-test p = .013).
This table shows molecular features associated with RPL26P28 in patient tissues and cancer cell lines. In patient samples, RPL26P28 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set.
